EVALUATION OF PROTEASE ACTIVATED RECEPTOR (PAR) ANTAGONISTS

蛋白酶激活受体 (PAR) 拮抗剂的评价

• 批准号: 8173270
• 负责人: Andras Gruber
• 金额: $ 4.76万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-05-01 至 2011-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8173270
• 关键词: 2-cyclopentyl-5-(5-isoquinolylsulfonyl)-6-nitro-1H-benzo(D)imidazole; Area; Computer Retrieval of Information on Scientific Projects Database; Disease; Evaluation; F2R gene; Funding; Grant; Hemostatic function; Institution; Proteinase-Activated Receptors; Research; Research Personnel; Research Project Grants; Resources; Source; Testing; Therapeutic; Thrombosis; United States National Institutes of Health; in vivo

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. We continue our collaborative research with Bayer Schering Pharma in areas of in thrombosis and hemostasis. We are engaged in a research project to generate definitive information whether PAR1 antagonists provided by Bayer have therapeutic potential for treatment of thromboembolic diseases. First, five compounds will be evaluated ex vivo, and 1 compound will be tested in vivo. Subsequently, three compounds will be evaluated ex vivo, and two compounds will be evaluated in vivo.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 我们继续与拜耳先灵制药在血栓形成和止血领域进行合作研究。我们正在进行一项研究项目，以获取拜耳提供的 PAR1 拮抗剂是否具有治疗血栓栓塞性疾病的潜力的明确信息。首先，将在体外评估 5 种化合物，并在体内测试 1 种化合物。随后，将在体外评估三种化合物，并在体内评估两种化合物。